Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Cash & Equivalents: 2021-2024

Historic Cash & Equivalents for ARS Pharmaceuticals (SPRY) over the last 4 years, with Dec 2024 value amounting to $50.8 million.

  • ARS Pharmaceuticals' Cash & Equivalents rose 50.18% to $59.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $59.6 million, marking a year-over-year increase of 50.18%. This contributed to the annual value of $50.8 million for FY2024, which is 28.40% down from last year.
  • As of FY2024, ARS Pharmaceuticals' Cash & Equivalents stood at $50.8 million, which was down 28.40% from $71.0 million recorded in FY2023.
  • ARS Pharmaceuticals' Cash & Equivalents' 5-year high stood at $210.5 million during FY2022, with a 5-year trough of $50.8 million in FY2024.
  • Moreover, its 3-year median value for Cash & Equivalents was $71.0 million (2023), whereas its average is $110.8 million.
  • In the last 5 years, ARS Pharmaceuticals' Cash & Equivalents surged by 250.50% in 2022 and then tumbled by 66.29% in 2023.
  • Yearly analysis of 4 years shows ARS Pharmaceuticals' Cash & Equivalents stood at $60.1 million in 2021, then spiked by 250.50% to $210.5 million in 2022, then tumbled by 66.29% to $71.0 million in 2023, then decreased by 28.40% to $50.8 million in 2024.